A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study)

What Was Tested

The paper reports a study of Carnosine, published as a randomized controlled trial.

Oral mucositis (OM) is a common complication in haematopoietic stem cell transplantation (HSCT).

Why It Was Studied

ACTRN12320001188921 (Date Registered: 10th November 2020).

Who Took Part

The age groups tagged for this paper are adults.

Adult patients who received conditioning regimens at moderate to high risk of developing OM were included.

The secondary endpoints included duration of grades 3-4 OM, incidence and duration of grades 2-4 OM, patient-reported pain and functional limitations.

How the Study Was Run

The design is described as randomized and open-label.

The participants were allocated by chance, so the Carnosine group and the comparison group should start out alike.

Being open-label, the Carnosine study did not mask who received what.

The primary endpoint was the incidence of severe (WHO grades 3-4) OM.

What Was Measured

Topics PubMed links to this paper include Carnosine, Hematopoietic Stem Cell Transplantation, Pain, Stomatitis, Organometallic Compounds and Zinc Compounds.

The authors tagged it with the keywords Haematopoietic stem cell transplantation, Oral mucositis, Polaprezinc and Zinc L-carnosine.

What This Means in Plain Language

The paper is a randomized and open-label study of Carnosine.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer), a journal based in Germany.

More context: the Carnosine compound page, all human trials.